Ziwig

Ziwig is a Paris-based, private diagnostics company pioneering a novel AI-powered platform that analyzes salivary RNA to detect diseases, starting with endometriosis. Its first product, Ziwig Endotest®, is a CE-marked in vitro diagnostic device that uses a saliva sample and next-generation sequencing to identify miRNA biomarkers, offering a reliable, non-invasive alternative to surgical diagnosis. The company operates an integrated ecosystem from R&D at the Paris Brain Institute to its own high-throughput lab, Ziwig Lab, positioning itself to expand its platform into other female pathologies and potentially beyond.

AI-powered platform analyzing salivary RNA (miRNA) via next-generation sequencing (NGS) to identify disease-specific transcriptomic signatures for non-invasive diagnosis.

Ziwig is a first-mover with a CE-marked saliva-based RNA test for endometriosis, competing against traditional laparoscopic diagnosis and other emerging non-invasive blood-based biomarker or imaging tests. Its integrated AI/RNA platform provides a distinct technological edge, but it may face competition from larger diagnostic companies with broader sales forces as the market matures.